BioAtla, Inc. (NASDAQ:BCAB) Shares Bought by Tang Capital Management LLC

Tang Capital Management LLC raised its holdings in BioAtla, Inc. (NASDAQ:BCAB) by 57.2% during the 4th quarter, Holdings Channel reports. The firm owned 1,374,076 shares of the company’s stock after purchasing an additional 500,000 shares during the quarter. Tang Capital Management LLC’s holdings in BioAtla were worth $812,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Jacobs Levy Equity Management Inc. purchased a new stake in shares of BioAtla in the fourth quarter valued at about $383,000. Anson Funds Management LP purchased a new position in shares of BioAtla during the fourth quarter valued at approximately $2,720,000. Acorn Capital Advisors LLC purchased a new position in shares of BioAtla during the fourth quarter valued at approximately $2,384,000. Boxer Capital Management LLC purchased a new position in shares of BioAtla during the fourth quarter valued at approximately $406,000. Finally, Jane Street Group LLC lifted its stake in shares of BioAtla by 204.1% during the fourth quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock valued at $88,000 after buying an additional 100,204 shares during the period. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Stock Performance

Shares of BCAB opened at $0.40 on Monday. The company has a market capitalization of $23.37 million, a price-to-earnings ratio of -0.24 and a beta of 1.01. BioAtla, Inc. has a 1 year low of $0.24 and a 1 year high of $2.87. The company’s 50 day simple moving average is $0.38 and its 200 day simple moving average is $0.74.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.01). Equities analysts expect that BioAtla, Inc. will post -1.46 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating on shares of BioAtla in a research note on Monday, March 31st.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.